Anti-Inflammatory and Anti-Angiogenic Airway Stents: A Step Forward in Tracheal Restenosis Prevention

Study Background and Research Question

Airway stenting remains a cornerstone intervention for patients suffering from tracheal stenosis, providing immediate relief from airway obstruction. However, the long-term efficacy of both silicone and self-expanding metallic stents is undermined by the high incidence of tracheal in-stent restenosis (TISR)—a complex pathological process involving persistent inflammation, excessive angiogenesis, and fibroblast activation. Granulation tissue hyperplasia, fueled by these processes, frequently leads to lumen narrowing and clinical recurrence, motivating the search for advanced stent solutions. The central research question addressed by Zhao et al. (2025) is whether a stent engineered to deliver both anti-inflammatory and anti-angiogenic agents can effectively modulate the tracheal microenvironment and suppress TISR more robustly than previous approaches.

Key Innovation from the Reference Study

The study’s principal innovation lies in the design and fabrication of a dual-action airway stent (PAGL) that integrates anlotinib hydrochloride—a multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties—alongside silver nanoparticles for their anti-inflammatory and antibacterial effects. Utilizing advanced electrospinning technology, the research team created a stent with tailored hydrophobic surface properties, optimized drug-release kinetics, and enhanced mechanical strength. This design enables targeted delivery of both agents directly at the site of stent placement, counteracting both excessive vascularization and the inflammatory cascade that drive restenosis.

Methods and Experimental Design Insights

The stents were constructed via electrospinning, enabling fine control over fiber morphology, drug encapsulation, and surface characteristics. Mechanical testing confirmed the stents’ resilience and suitability for airway deployment. Drug-release kinetics were assessed to ensure sustained local bioavailability. In vitro assays involved human umbilical vein endothelial cells (HUVECs) and lung fibroblasts to quantify anti-proliferative and anti-angiogenic effects. Antibacterial efficacy was validated against methicillin-resistant Staphylococcus aureus (MRSA).

For in vivo studies, PAGL stents were implanted into the tracheae of New Zealand rabbits. The efficacy endpoints included histological analysis of inflammatory cell infiltration, angiogenesis (via microvessel density), fibroblast activation, and granulation tissue formation. RNA sequencing provided a transcriptomic perspective, identifying changes in gene expression related to fibrosis, intimal hyperplasia, and cell migration.

Core Findings and Why They Matter

According to the reference study, the PAGL stent delivered several clinically relevant outcomes:

• Potent Anti-Inflammatory Effects: The combined action of anlotinib and silver nanoparticles suppressed local inflammatory responses, as evidenced by reduced infiltration of inflammatory cells and downregulation of pro-fibrotic and pro-inflammatory gene signatures.
• Anti-Angiogenic Activity: In vitro, the stent inhibited HUVEC proliferation and tube formation. In vivo, a marked reduction in microvessel density within the stented tracheal segments was observed, supporting attenuation of pathological angiogenesis.
• Prevention of Fibrosis and Granulation: RNA sequencing revealed significant downregulation of genes associated with fibrosis and intimal hyperplasia. Histology corroborated these findings, showing less granulation tissue formation and reduced fibroblast activation.
• Antibacterial Efficacy: The stent achieved near-complete eradication of MRSA in vitro, addressing the risk of stent-associated infection and secondary inflammation.

Collectively, these results demonstrate that simultaneous targeting of inflammation and angiogenesis can synergistically prevent the cascade leading to TISR, representing a significant step beyond single-modality stent designs. The integration of transcriptomic analysis provides robust mechanistic insight, linking phenotypic improvements to molecular changes.

Comparison with Existing Internal Articles

While the present study focuses on a dual-agent stent platform for modulating tracheal tissue responses, previous internal articles have explored the inhibition of key inflammatory pathways, such as NF-κB, using small molecule IKK inhibitors like BMS-345541 hydrochloride. For example, the article “BMS-345541 Hydrochloride: Selective IKK/NF-κB Pathway Inh...” discusses how targeted inhibition of IκB kinase can disrupt NF-κB-dependent transcription of pro-inflammatory cytokines, reducing inflammation and promoting apoptosis in cancer biology research and T-cell acute lymphoblastic leukemia models. Similarly, “BMS-345541 Hydrochloride: A Precision IKK Inhibitor for Translational Inflammation and Cancer Research” highlights the compound’s utility in dissecting inflammatory signaling and apoptosis induction in T-ALL.

Compared to these pathway-focused strategies, the airway stent study innovates at the interface of material science and pharmacology, delivering localized, dual-modality therapy with demonstrated anti-infective, anti-inflammatory, and anti-angiogenic effects. Both approaches underscore the principle that precise modulation of inflammation—whether systemic or localized—can yield superior outcomes in tissue repair and disease mitigation.

Limitations and Transferability

Despite the promising preclinical results, there are important limitations to consider. The in vivo work was conducted in rabbits, whose airway size and immune responses differ from humans. Long-term safety, stent migration risk, and the potential for resistance or adverse tissue reactions require evaluation in larger animals and, ultimately, clinical trials. Furthermore, while the dual-action approach is compelling, the scalability and regulatory pathway for combination stents with embedded drugs and nanoparticles remain to be clarified.

Transferability to other stented tissues (e.g., vascular, biliary) is theoretically attractive, but direct evidence is lacking and would require domain-specific validation. The study does, however, establish a robust platform for future translational research on device-based combinatorial therapies.

Protocol Parameters

• Stent implantation: PAGL stents were placed in the tracheae of New Zealand rabbits under sterile conditions; follow-up ranged up to several weeks for assessment of tissue responses.
• In vitro anti-angiogenesis assays: HUVECs were exposed to stent extracts; proliferation and tube formation were quantified over 24–48 hours.
• Gene expression analysis: RNA sequencing was performed on tracheal tissues post-stent implantation to identify differential expression relevant to fibrosis and inflammation.
• Bacterial eradication tests: MRSA cultures were treated with stent material; bacterial viability was assessed after defined incubation periods.
• Workflow recommendation: For researchers modeling airway inflammation or investigating anti-fibrotic device strategies, parallel in vitro and in vivo protocols are advisable, with multi-parametric readouts (histology, transcriptomics, microbiology).

Research Support Resources

For researchers interested in dissecting the molecular and cellular mechanisms underpinning inflammation and fibrosis—whether in stent-based models or broader contexts such as apoptosis induction in T-ALL or cancer biology research—the use of highly selective IKK inhibitors offers complementary mechanistic insight. BMS-345541 hydrochloride (SKU A3248) from APExBIO is a well-characterized small molecule that can be integrated into cell-based or animal protocols for precise inhibition of NF-κB signaling, as highlighted in internal literature. Its robust solubility and selectivity profile make it suitable for studies aiming to elucidate the role of IKK/NF-κB in inflammation research and tissue remodeling.